Regarding the method of analysis that sonus used for their phase 3 data, remember when the sage of the pacific northwest is on record as saying that the FDA now wants Sonus to analyze the data in a different way, and that this is the first instance he's ever heard in his 18? year history in the business? Besides Molecular Bio having done it the right way, prior to Quay's statement in the now FAMOUS conference call...
DIATIDE, stock symbol DITI. They develop peptide based imaging agents for nuclear imaging. Well, I wonder if Diatide told its reviewers which images were the "before" and "after" images and then asked which were better. Duh. Check it out. Based on the shoddy data and analysis from Sonus, I am becoming more suspicious of echogen's safety and efficacy - if they had nothing to hide regarding these issues, then why would they have analyzed the data in a micky mouse fashion? If then, it was done to hide or enhance the results submitted to FDA, (Europe, too), we should assume that clean data will look worse, raising the potential of the product never being approved.
I, for one, being an altruist, educator, bon-vivant, and saint...have to raise the issue of ethics on the part of sell side analysts who are sticking with their buy opinions on the stock because Sonus may be a corporate finance client of their respective brokerage firms. Some of these analysts may in fact, have the CFA - Certified Financial Analyst designation. Part of earning a CFA is an ethics oath. One can make a case that continuing to recommend this stock would be violating the CFA charter.
On other threads, (sorry to digress), threads which up until the arrival of a dissenter, have been 99 44/100% populated by people bullish on a stock, when people start to drift in and question the bullish scenario (rose colored glasses), the new guy/girl in town is occasionally accused of lying, misrepresenting him/herself, and/or engaging in trying to manipulate the stock. The stock manipulation theory applies to the brokerage firms, I think. Often, sell side analysts are pressured to maintain buy opinions on stocks despite deteriorating fundamentals. How many times does anyone see "sell" opinions published from the brokerage houses? ---end of sermon |
